- Aspect Biosystems, a biotechnology company pioneering microfluidic 3D bioprinting of human tissues, announced it raised $20 million in Series A
Aspect Biosystems — a biotechnology company pioneering microfluidic 3D bioprinting of human tissues — announced recently that it raised $20 million in Series A funding.
Radical Ventures led the round with participation from existing and new investors, including Pangaea Ventures, Pallasite Ventures, and Rhino Ventures. And Aspect will use the funding to advance multiple tissue therapeutic programs, expand its technology platform capabilities, and grow its team.
“We are thrilled to close this important institutional financing round with a group of world-class investors who believe in our bold vision,” said Tamer Mohamed, CEO at Aspect Biosystems. “This funding speaks to the power of our technology and strategy in addressing multiple applications in therapeutic discovery and regenerative medicine, and will allow us to accelerate internal innovation and expand our global partnerships. With our technology platform, interdisciplinary team of scientists and engineers, and leading collaborators, we are developing a new wave of solutions that have the potential to transform how we heal injury and disease.”
Aspect’s broadly applicable technology platform enables the creation of living human tissues with unprecedented control, flexibility, and precision. Along with Aspect’s internal tissue therapeutic programs for regenerative medicine, the company works with its global partners to create high-value solutions that will transform medical research and clinical practice.
“We are very excited to partner with the excellent Aspect team to support the growth of their world-leading 3D bioprinting platform and the development of breakthrough technologies aimed at radically transforming human health,” added Jordan Jacobs, managing partner at Radical Ventures.
